The European Medicines Agency has given its authorization for the use of vaccines against the omicron variant of COVID-19 to both Moderna and BioNTech-Pfizer.
The EU’s drug regulator, the European Medicines Agency (EMA), said on Thursday that it had given the green light to two vaccines that target the omicron variant of COVID-19.
The vaccines were developed by the US-German partnership BioNTech-Pfizer and by the US company Moderna.
The vaccines are the first to target the omicron variant BA.1, as well as being effective against the original strain of the virus. Both also produced vaccines against the first iteration of the virus that were approved by the EMA.